Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Numinus Wellness announces design and protocol for their Phase 1 clinical trial

Numinus Wellness announces design and protocol for their Phase 1 clinical trial

Numinus Wellness CEO Payton Nyquvest joined Steve Darling from Proactive to share news the company has finalized the study design and protocol for their Phase 1 clinical trial on a naturally derived Psilocybin extract.

Nyquvest telling Proactive the Phase I clinical trial will use both PSYBINA RX and the Psilocybin comparator and will be conducted at Numinus' clinical site in Vancouver, BC on 14 healthy volunteers.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK